Shandong Weigao Medical Polymer : 17/08/2016 ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2016

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

For the six months ended 30 June 2016 (the "Period"), the unaudited turnover of Shandong Weigao Group Medical Polymer Company Limited (the "Company") and its subsidiaries (the "Group") was approximately RMB3,195,426,000, representing an increase of approximately 11.1% over approximately RMB2,876,884,000 for the same period last year.

Excluding extraordinary items, net profit attributable to owners of the Company was approximately RMB632,509,000 (same period in 2015 of approximately RMB588,021,000), representing an increase of approximately 7.6% when compared with the same period last year.

The unaudited net profit attributable to the shareholders of the Group for the six months ended 30 June 2016 was approximately RMB385,500,000, representing a decrease of approximately 34.0% over approximately RMB584,374,000 for the same period last year. The total amounts for extraordinary items for the Period were approximately RMB247,009,000, of which RMB238,860,000 was a share-based payment arised from the subscription of Weigao Orthopaedic shares by the orthopaedic management and was a non- cash and one-off item.

* For identification purpose only

During the Period, (1) turnover of single-use consumables was approximately RMB2,351,510,000, representing an increase of approximately 10.7% when compared with the same period last year; (2) turnover of orthopaedic products was approximately RMB340,512,000, representing an decrease of approximately 4.3% when compared with the same period last year; and (3) turnover of blood purification business was approximately RMB503,404,000, representing an increase of approximately 27.1% over the same period last year.

The Board of Directors (the "Board") recommends the distribution of an interim dividend of RMB0.041 per share for the six months ended 30 June 2016 (same period in 2015: RMB0.039 per share). The proposal is subject to the approval by the shareholders of the Company (the "Shareholders") at the forthcoming special general meeting.

The Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended 30 June 2016, together with the unaudited comparative figures for the same period in 2015 as follows:

Unaudited

For the six months ended 30 June

Profit for the Period 366,488 603,120

Profit for the Period attributable to:

Owners of the Company 8 385,500 584,374

Non-controlling interest (19,012) 18,746

366,488 603,120

Total comprehensive income attributable to:

Owners of the Company 388,743 584,258

Non-controlling interest (19,012) 18,746

369,731 603,004